Ask AI
ProCE Banner Activity

Once-Weekly Oral ISL + LEN in People Living With Virologically Suppressed HIV: Wk 96 Results

Conference Coverage
Slideset

In this phase II trial, people living with virologically suppressed HIV who switched from stable daily oral ART to once-weekly oral islatravir plus lenacapavir maintained a high rate of virologic suppression through Week 96, with no clinically relevant decreases in CD4+ cell counts or lymphocyte counts.

Released: October 23, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare